News

Medika Natura CEO, Abdul Razak Mohd Isa, has been appointed as subject matter expert in research and development (R&D) with the Malaysian Ministry of Science, Technology and Innovation (MOSTI) Part of the job scope of the three-year appointment involves providing...

Medika Natura CEO, Abdul Razak Mohd Isa, has been appointed as an Adjunct Professor at the Institute of Systems Biology (INBIOSIS) at the National University of Malaysia (UKM) Razak’s two-year appointment will involve connecting INBIOSIS with research and industry...

Phase 2 clinical studies of SKF7™ conducted in Indonesia is the first Malaysian-led anti-obesity study to be registered on ClinicalTrials.gov, the world’s largest clinical trial database. Medika Natura has initiated Phase 2 in-human clinical trials on its proprietary...

Medika Natura’s proprietary product SKF7™ is the first native Malaysian ingredient to be officially listed on Regulations.gov Medika Natura’s proprietary product SKF7™ is the first native Malaysian ingredient to be listed on the Regulations.gov website and the first...

Medika Natura CEO and COO Abdul Razak Mohd Isa and Mustadza Muhamad presented to international investors and distributors at The Nutritional Capital Network Investor Meeting (NCNIM) 2020. The objective of the presentation which took place last October, was to attract...

Medika Natura CEO, Abdul Razak Mohd Isa, drew a record number of 140 attendees to his talk, which was part of the University Technology Malaysia (UTM) MTDC CEO lecture series. Held over Zoom last November, the digital lecture entitled “Membangun Perniagaan yang Mampan...

The recent death of “Black Panther” star Chadwick Boseman at the age of 43 highlighted the disproportionate effect colon cancer has on men of African descent. In fact, colon cancer is 30% more common in men than women, with people of African descent having the highest...

A Phase 2 clinical trial of SK7™ is the first ever study of its kind to be launched in clinics and hospitals across Malaysia, India and Indonesia. Medika Natura has initiated Phase 2 clinical trials of its proprietary bio-extract SKF7™ in general hospitals and clinics...

SKF7™ approved to be sold in the United States via Amazon Medika Natura’s flagship ingredient, SKF7™ is set to reach American shores by early 2021 via Amazon following USFDA approval.

Obese individuals who contract Covid-19 are seven times more likely to develop severe symptoms than people of normal/healthy weight. A study published by the Obesity Society indicated that the odds of developing severe Covid-19 symptoms are seven times higher in obese...